Clinical Trial: Ropeginterferon for Treatment Free Remission
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: CML (Chronic Myelogenous Leukemia)
Study Type: INTERVENTIONAL
Official Title: A Feasibility Study of Ropeginterferon for Treatment Free Remission in CML Patients Who Have a Sustained Deep Molecular Response
Brief Summary:
Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co. and the pegylated (PEG) formulations that require less frequent administration and have improved efficacy and tolerability.In this study, patients in the investigational arm will receive Ropeginterferon subcutaneously with 250 ?g at week 0, 350 ?g at week 2, 500 ?g at week 4, and thereafter 500 ?g bi-weekly until week 24.
Read more